Tag: biotechnology

  • Texas Health Center Studying Newborns Strep Test

    The University of Texas Health Science Center at Houston is studying a faster lab test for Group B Strep (GBS), a common cause of life-threatening infections in newborns. The lab test is made by NanoLogix Inc., a biotech company in Hubbard, Ohio. According to the U.S. Centers for Disease Control and Prevention (CDC), GBS is…

  • Alsace, Québec Consortia to Collaborate on Drug Discovery

    Alsace BioValley, in Illkirch-Graffenstaden, France, a health science cluster and Québec Consortium for Drug Discovery in Nuns’ Island, Québec, Canada, signed in Paris today an agreement for a bilateral partnership to benefit Alsatian and Québec research centers and industries in the health and life sciences. The agreement calls for co-financing of R&D collaborative projects in…

  • University Licenses Nanoparticle Drug Delivery Technology

    The University of British Columbia (UBC) and the Centre for Drug Research and Development (CDRD), both in Vancouver, Canada, said today that Covidien, a Dublin, Ireland provider of health care products, has licensed a drug-delivery platform technology invented by UBC researcher, Pieter Cullis. CDRD provided the development facilities and commercialization services that led to this…

  • Pfizer, Diagnostics Company to Collaborate on Sepsis Tests

    SIRS-Lab,a molecular diagnostics company in Jena, Germany and Pfizer Pharma GmbH in Berlin said today they plan to collaborate in the field of sepsis. The collaboration aims to develop molecular diagnostic tests for early and accurate targeting of anti-infection therapy. Sepsis is a life-threatening illness caused by the body’s response to a bacterial infection. The…

  • FDA Clears Protein Test for Heart Failure Prognosis

    BG Medicine Inc., a Waltham, Massacusetts developer of molecular diagnostics using biomarkers, says that the U.S. Food and Drug Administration (FDA) has cleared the company’s galectin-3 test to help assess the prognosis of patients diagnosed with chronic heart failure. The company says this 510(k) clearance is the first time FDA has cleared a test to…

  • U.S., Europe Patents Issued for RNAi Drug Delivery

    Tekmira Pharmaceuticals Corp. in Vancouver, Canada, a developer of RNA interference (RNAi) therapeutics, says that the United States Patent and Trademark Office (USPTO) and European Patent Office (EPO) have issued patents covering elements of Tekmira’s lipid nanoparticle technology for delivering nucleic acid therapeutics, including small interfering RNA (siRNA). RNAi therapeutics have the potential to treat…

  • FDA Approves Drug for Cancer-Related Bone Deterioration

    Amgen Inc., a biotechnology company in Thousand Oaks, California, said the U.S. Food and Drug Administration (FDA) has approved its drug XGEVA (denosumab), for the prevention of skeletal-related events in patients with bone cancers from solid tumors. The company says FDA approved XGEVA following a 6 month priority review by the FDA, a process reserved…

  • Life Sciences Venture Network Launches in New York

    The New York Academy of Sciences plans to kick off the Life Science Angel Network (LSAN) at the academy’s lower Manhattan headquarters on Thursday 18 November. The new investment network is expected to connect scientists and entrepreneurs with funding to support commercialization of discoveries in biotechnology, medical devices, and health care informatics. The academy says…

  • Late Stage Trial Shows Parkinson’s Drug Efficacy

    Biotechnology company Impax Laboratories Inc. in Hayward, California  says that a Phase 3 clinical trial of its drug IPX066 shows it is effective in patients with early Parkinson’s disease (PD), with side effects similar to related PD drugs in use. A Phase 3 trial studies a drug or treatment given to large groups of people…

  • Genzyme Sells Diagnostics Business to Sekisui Chemical

    Genzyme Corporation, a biotechnology company in Cambridge, Massachusetts said today that it has an agreement with Sekisui Chemical Co., Ltd., which will acquire Genzyme’s diagnostic products business for $265 million in cash. Sekisui Chemical is a manufacturer of plastic materials for automotive and medical products, as well as PVC pipe systems and fabricated housing headquartered…